Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (26673)	11/25/1998 11:52:00 AM
From: Henry Niman	Respond to of 32384

bob, Lehman also forecasts a profit for 1999 of $0.08 (although they say $0.10 in the text), so at this time, I don't think that any analyst is projecting a loss for next year (I think that this is the first 1999 estimate for Lehman). The report is also linked to: paradise-web.com

To: Machaon who wrote (26673)	11/25/1998 12:00:00 PM
From: aknahow	Read Replies (2) \| Respond to of 32384

I have asked on another thread, and perhaps none of us know, but was the panel member with AIDs on the panel to represent patients or was he a scientist/doctor who also just happened to have the disease? " I found it interesting that the AIDS patient on the panel, who was the only one who voted against approval, said that a reason that he voted against Panretin Gel for KS was because he felt that there would be limited demand for the product, since there were very few new cases of KS." Is this really correct. I thought the motive or reasoning was that the drug caused pain and redness for essentially a cosmetic procedure. It is difficult to imagine anyone on a panel turning down a drug based on the panel members view of the market for the drug.